Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URN010
MIFTS: 58

Urinary Tract Obstruction

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Urinary Tract Obstruction

About this section

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 15 17 74
Obstructive Uropathy 12 56 15
Urinary Obstruction 12
Urologic Diseases 74

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:5200
ICD9CM 36 599.6 599.60
NCIt 51 C3675 C79805
SNOMED-CT 69 7163005
ICD10 34 N13.9
Sources

Summaries for Urinary Tract Obstruction

About this section
MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to obstructive nephropathy and interstitial cystitis, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary Tract Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are HIV Life Cycle and Cytokine Signaling in Immune system. The drugs Tamsulosin and Adrenergic alpha-1 Receptor Antagonists have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and testes, and related phenotypes are growth/size/body region and homeostasis/metabolism

Sources

Related Diseases for Urinary Tract Obstruction

About this section

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 obstructive nephropathy 31.2 ALB EGF REN SMAD2 SMAD3 TGFB1
2 interstitial cystitis 30.5 EGF HBEGF UMOD
3 acute cystitis 30.5 ALB CCL2 KLK3
4 cystitis 30.4 CCL2 EGF HBEGF PTGS2 UMOD
5 cystic kidney disease 30.2 ALB B2M EGF UMOD
6 pyelonephritis 30.1 ALB CCL2 NAGLU UMOD
7 ureteral obstruction 30.0 AQP2 PTGS2 TGFB1
8 vesicoureteral reflux 1 30.0 NAGLU REN UMOD
9 end stage renal failure 30.0 ALB FN1 TGFB1 UMOD
10 clear cell adenocarcinoma 29.9 KLK3 SMAD2 SMAD3
11 adenocarcinoma 29.8 EGF PIK3CA PTGS2 SMAD3
12 hydronephrosis 29.5 ALB AQP2 B2M CCL2 EGF NAGLU
13 renal fibrosis 28.9 CCL2 CCN2 REN SMAD2 SMAD3 TGFB1
14 kidney disease 28.3 ALB AQP2 B2M CCL2 CCN2 NAGLU
15 kashani strom utley syndrome 11.8
16 renal hypodysplasia/aplasia 1 11.4
17 cystinuria 11.4
18 renal hypodysplasia/aplasia 2 11.4
19 renal hypodysplasia/aplasia 3 11.3
20 congenital anomalies of kidney and urinary tract 2 11.2
21 small cell carcinoma of the bladder 11.0
22 submandibular gland disease 10.4 KLK3 TGFB1
23 adult hepatocellular carcinoma 10.4 EGF PIK3CA
24 ascending cholangitis 10.4 ALB CCL2 TGFB1
25 calcifying aponeurotic fibroma 10.3 EGF FN1
26 lipoid nephrosis 10.3 ALB CCL2 NAGLU
27 tuberculous meningitis 10.3 CCL2 GGT1 TGFB1
28 prostate transitional cell carcinoma 10.3 KLK3 PIK3CA
29 immunodeficiency 43 10.3 ALB B2M
30 prostate adenoid cystic carcinoma 10.3 KLK3 PIK3CA
31 inguinal hernia 10.3
32 diabetic foot ulcers 10.3 CCL2 TGFB1
33 peyronie's disease 10.3 CCL2 SMAD3 TGFB1
34 proteasome-associated autoinflammatory syndrome 1 10.3 ALB CCL2 PTGS2
35 benign essential hypertension 10.2 ALB REN
36 prostate cancer 10.2
37 prostate cancer, hereditary, 8 10.2
38 prostate cancer, hereditary, 6 10.2
39 aortic aneurysm 10.2
40 peritonitis 10.2 ALB B2M CCL2
41 membranous nephropathy 10.2 ALB B2M TGFB1
42 leukoregulin 10.2 PTGS2 TGFB1
43 non-secretory myeloma 10.2 ALB B2M FN1
44 intestinal disease 10.2 ALB PIK3CA PTGS2
45 aortic aneurysm, familial abdominal, 1 10.2
46 bladder cancer 10.2
47 systemic lupus erythematosus 10.2
48 crohn's disease 10.2
49 lupus erythematosus 10.2
50 retroperitoneal fibrosis 10.2

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 21)


Acute Cystitis Acute Kidney Failure
Bladder Cancer Bladder Neck Obstruction
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Paralytic Ileus
Prostate Calculus Prostate Cancer
Prostatic Hypertrophy Prostatitis
Protein-Energy Malnutrition Ureterolithiasis
Urethral Stricture

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction
Sources

Symptoms & Phenotypes for Urinary Tract Obstruction

About this section

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, urgency of micturition, other and unspecified genitourinary symptoms, renal colic, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 AQP2 B2M CCN2 EGF FN1 GGT1
2 homeostasis/metabolism MP:0005376 10.4 ALB AQP2 B2M CCN2 FN1 GGT1
3 behavior/neurological MP:0005386 10.35 AQP2 GGT1 HBEGF NAGLU PIK3CA PTGS2
4 cardiovascular system MP:0005385 10.35 B2M CCN2 FN1 HBEGF NAGLU PIK3CA
5 immune system MP:0005387 10.35 B2M CCL2 EGF FN1 GGT1 NAGLU
6 cellular MP:0005384 10.34 ALB B2M CCN2 FN1 GGT1 NAGLU
7 mortality/aging MP:0010768 10.31 ALB AQP2 B2M CCN2 FN1 GGT1
8 endocrine/exocrine gland MP:0005379 10.28 ALB B2M CCN2 EGF GGT1 PIK3CA
9 integument MP:0010771 10.27 AQP2 B2M CCN2 EGF FN1 GGT1
10 hematopoietic system MP:0005397 10.25 AQP2 B2M FN1 GGT1 NAGLU PTGS2
11 digestive/alimentary MP:0005381 10.2 ALB B2M CCN2 EGF PTGS2 SLC5A6
12 liver/biliary system MP:0005370 10.13 ALB B2M CCN2 FN1 NAGLU PTGS2
13 nervous system MP:0003631 10.06 B2M FN1 HBEGF NAGLU PIK3CA PTGS2
14 neoplasm MP:0002006 9.97 ALB B2M FN1 PIK3CA PTGS2 SMAD2
15 renal/urinary system MP:0005367 9.96 ALB AQP2 GGT1 NAGLU PTGS2 REN
16 reproductive system MP:0005389 9.9 AQP2 B2M EGF FN1 GGT1 PIK3CA
17 skeleton MP:0005390 9.73 CCN2 FN1 GGT1 HBEGF NAGLU PIK3CA
18 vision/eye MP:0005391 9.28 CCN2 EGF GGT1 NAGLU PIK3CA PTGS2
Sources

Drugs & Therapeutics for Urinary Tract Obstruction

About this section

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106133-20-4 129211
2 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
3 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Muscarinic Antagonists Phase 4
6 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
7 Cholinergic Antagonists Phase 4
8 Cholinergic Agents Phase 4
9 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Tolterodine tartrate Phase 4 124937-52-6
11
Indomethacin Approved, Investigational Phase 3 53-86-1 3715
12
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
13
Leuprolide Approved, Investigational Phase 3,Phase 2 53714-56-0 657181 3911
14
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
15
Goserelin Approved Phase 3,Phase 2 65807-02-5 5311128 47725
16
Nilutamide Approved, Investigational Phase 3 63612-50-0 4493
17
Salicylic acid Approved, Investigational, Vet_approved Phase 3 69-72-7 338
18
Bicalutamide Approved Phase 3 90357-06-5 2375 56069
19
Flutamide Approved, Investigational Phase 3 13311-84-7 3397
20
Artemether Approved Phase 3 71963-77-4 68911 119380
21
Acetaminophen Approved Phase 3 103-90-2 1983
22
Artesunate Approved, Investigational Phase 3 88495-63-0 5464098 6917864
23
Lumefantrine Approved Phase 3 82186-77-4 6437380
24
Cortisone Experimental Phase 3 53-06-5 222786
25 Anti-Bacterial Agents Phase 3
26 Antibiotics, Antitubercular Phase 3
27 Anti-Infective Agents Phase 3,Phase 1
28 carnitine Phase 3
29 Omega 3 Fatty Acid Phase 3
30 Vasopressins Phase 3
31 Natriuretic Agents Phase 3
32 Coagulants Phase 3
33 Cyclooxygenase Inhibitors Phase 3
34 arginine Phase 3
35 Arginine Vasopressin Phase 3
36 Antirheumatic Agents Phase 3
37 Anti-Inflammatory Agents Phase 3,Phase 2
38 Hemostatics Phase 3
39 Analgesics, Non-Narcotic Phase 3
40 Deamino Arginine Vasopressin Phase 3
41 Tocolytic Agents Phase 3
42 Anti-Inflammatory Agents, Non-Steroidal Phase 3
43 Peripheral Nervous System Agents Phase 3
44 Analgesics Phase 3
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
46 Hormones Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Hormonal Phase 3,Phase 2
48 Hormone Antagonists Phase 3,Phase 2
49 glucocorticoids Phase 3,Phase 2
50 Androgens Phase 3,Phase 2

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Completed NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
2 Functional MR Urography Completed NCT00301470 Phase 4
3 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
4 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
5 Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic Unknown status NCT01742689 Phase 3 Desmopressin intranasal spray;Placebo intranasal spray;Indomethacin suppository
6 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3 Omexel;spasfon
7 Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Recruiting NCT03678025 Phase 3 Abiraterone;Bicalutamide;Degarelix;Docetaxel;Flutamide;Goserelin Acetate;Histrelin Acetate;Leuprolide Acetate;Nilutamide;Prednisone;Triptorelin
8 Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria Recruiting NCT03056391 Phase 3 Paracetamol
9 Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
10 Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
11 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed NCT01718353 Phase 2 DOCETAXEL (XRP6976);CABAZITAXEL (XRP6258);Prednisone
12 Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms Completed NCT02244281 Phase 2 tamsulosin hydrochloride;Placebo
13 Bipolar Androgen-based Therapy for Prostate Cancer (BAT) Completed NCT01750398 Phase 2 Testosterone cypionate;Goserelin;Leuprolide
14 Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Completed NCT00527488 Phase 2 Degarelix;Degarelix;Degarelix;Degarelix
15 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
16 Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery Recruiting NCT03541850 Phase 2 Antiandrogen Therapy
17 ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. Recruiting NCT02933801 Phase 2 ODM-201
18 Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Active, not recruiting NCT02286921 Phase 2 Testosterone cypionate;Enzalutamide;Testosterone Enanthate
19 Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation Terminated NCT01919346 Phase 2 Eculizumab;Normal Saline
20 A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma Completed NCT00315731 Phase 1
21 Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia Recruiting NCT03723564 Phase 1 Lactated Ringers Solution for Injection
22 Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria Unknown status NCT02139059 Not Applicable
23 Effect of Nephrostomy on Relative Function of Obstructed Kidney Completed NCT03936673 Not Applicable
24 Prostatic Artery Embolization for Obstructive Uropathy Due to Prostate Cancer Completed NCT03104907 Not Applicable
25 Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to BPH Under Tamsulosin Treatment Completed NCT03280420 Not Applicable
26 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia Completed NCT03055624 Not Applicable
27 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877 Not Applicable
28 Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage Completed NCT02055430 Not Applicable
29 Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) Completed NCT02398682 Not Applicable
30 Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men Completed NCT02330107 Not Applicable
31 Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO) Recruiting NCT03281798 Not Applicable
32 Standardized Prenatal Clinical Care for LUTO Recruiting NCT02315521
33 Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL) Recruiting NCT03605745 Not Applicable
34 Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate Recruiting NCT03034187
35 Short Course Radiation Therapy in Palliative Treatment of Pelvic Cancer Recruiting NCT03804333 Not Applicable
36 Renal Anhydramnios Fetal Therapy Recruiting NCT03101891 Not Applicable Isotonic fluid
37 Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients. Recruiting NCT03912558 Not Applicable
38 Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate Recruiting NCT03157726 Not Applicable
39 Green LEP vs ThuLEP vs HoLEP in Management of Marked Enlarged Prostate Active, not recruiting NCT03305861 Not Applicable
40 Indwelling Stent Discoloration Project Active, not recruiting NCT02007980
41 Ejaculation Preserving Photoselective Vaporization Versus Plasma Kinetic Vaporization Versus Transurethral Resection Of The Prostate: A RCT Enrolling by invitation NCT03589196 Not Applicable
42 Advanced Genital Prolapse Surgery With and Without Mid Urethral Sling to Prevent Stress Urinary Incontinence Enrolling by invitation NCT02578056 Not Applicable
43 Transobturator Subtrigonal Tape vs Transobturator Suburethral Tape for Stress Urinary Incontinence Not yet recruiting NCT02112591 Not Applicable
44 Fetal Cystoscopy for Lower Urinary Tract Obstruction Terminated NCT02446184 Not Applicable
45 Tc-99m Renography and Cisplatin-induced Nephrotoxicity Terminated NCT00213642
46 Functional, Dynamic, and Anatomic MR Urography Withdrawn NCT00585767

Search NIH Clinical Center for Urinary Tract Obstruction

Sources

Genetic Tests for Urinary Tract Obstruction

About this section
Sources

Anatomical Context for Urinary Tract Obstruction

About this section

MalaCards organs/tissues related to Urinary Tract Obstruction:

42
Kidney, Prostate, Testes, Cervix, Smooth Muscle, Colon, Spinal Cord
Sources

Publications for Urinary Tract Obstruction

About this section

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 1040)
# Title Authors Year
1
A potential serious complication in infants with congenital obstructive uropathy: Secondary pseudohypoaldosteronism. ( 30623923 )
2019
2
A classic twin study of lower urinary tract obstruction: Report of 3 cases and literature review. ( 29664229 )
2019
3
Antenatal staging of congenital lower urinary tract obstruction. ( 29978555 )
2019
4
Surgical interventions and anesthesia in the 1st year of life for lower urinary tract obstruction. ( 30049573 )
2019
5
The search for the definition and effective diagnosis of upper urinary tract obstruction: the Whitaker test then and now, Whitaker et al. 2018. ( 30528651 )
2019
6
First-year profile of biomarkers for early detection of renal injury in infants with congenital urinary tract obstruction. ( 30694385 )
2019
7
Congenital urinary tract obstruction. ( 30819578 )
2019
8
Cardiac findings and hemodynamic changes associated with severe lower urinary tract obstruction in utero. ( 30908816 )
2019
9
Atypical Causes of Urinary Tract Obstruction. ( 30937201 )
2019
10
Myocardial function in fetuses with lower urinary tract obstruction: Is there a cardiac remodeling effect due to renal damage? ( 30957256 )
2019
11
Outcome of fetuses with lower urinary tract obstruction and normal amniotic fluid volume in the second trimester of pregnancy: a single center experience. ( 30977189 )
2019
12
The role of renal biomarkers to predict the need of surgery in congenital urinary tract obstruction in infants. ( 30979613 )
2019
13
Biometric and morphological features of the fetal bladder in lower urinary tract obstruction on magnetic resonance imaging: new perspectives for fetal cystoscopy. ( 31006924 )
2019
14
Rare Variants in BNC2 Are Implicated in Autosomal-Dominant Congenital Lower Urinary-Tract Obstruction. ( 31051115 )
2019
15
Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy? ( 31061871 )
2019
16
Role of Percutaneous Nephrostomy in Bladder Carcinoma with Obstructive Uropathy: A Story Revisited. ( 30820102 )
2019
17
Common clinical markers predict end-stage renal disease in children with obstructive uropathy. ( 30317433 )
2019
18
Clinical Profile and Outcome of Children with Congenital Obstructive Uropathy. ( 30796705 )
2019
19
Bilateral Obstructive Uropathy Caused by Congenital Bladder Diverticulum Presenting as Hypertensive Retinopathy. ( 29441752 )
2018
20
Successful medical management of pseudomembranous cystitis in three cats with lower urinary tract obstruction. ( 29226304 )
2018
21
Hemoadsorption in a Case of Severe Septic Shock and Necrotizing Fasciitis Caused by Nontraumatic Renal Rupture due to Pyelonephritis with Obstructive Uropathy. ( 29854478 )
2018
22
An Interesting Case of a 57-Year-Old Male with an Upper Gastrointestinal Bleeding and Obstructive Uropathy with Bilateral Hydronephrosis Diagnosed with Systemic Mucormycosis. ( 30026991 )
2018
23
Obstructive Uropathy Secondary to an Indirect Extraperitoneal Ureteral Inguinal Hernia. ( 30841998 )
2018
24
Obstructive uropathy from complete bladder and bilateral ureteral incarceration within an inguinal hernia. ( 29487099 )
2018
25
Inguinal hernia causing extrinsic compression of bilateral ureters leading to chronic obstructive uropathy. ( 29644043 )
2018
26
Natural History of Fetal Lower Urinary Tract Obstruction with Normal Amniotic Fluid Volume at Initial Diagnosis. ( 28700992 )
2018
27
Fetal surgery for lower urinary tract obstruction: the importance of staging prior to intervention. ( 29160637 )
2018
28
Combined prostatic urethral lift and remodeling of the prostate and bladder neck: a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction. ( 29450732 )
2018
29
Current State of Fetal Intervention for Lower Urinary Tract Obstruction. ( 29468448 )
2018
30
Perinatal Outcomes of Fetal Lower Urinary Tract Obstruction After Vesicoamniotic Shunting Using a Double-Basket Catheter. ( 29498072 )
2018
31
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction. ( 29644715 )
2018
32
SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. ( 29852947 )
2018
33
The uroplakin plaque promotes renal structural integrity during congenital and acquired urinary tract obstruction. ( 29897287 )
2018
34
Long-term renal outcome in infants with congenital lower urinary tract obstruction. ( 29980359 )
2018
35
Extracorporeal membrane oxygenation support in a newborn with lower urinary tract obstruction and pulmonary hypoplasia: a case report. ( 30012211 )
2018
36
Prenatal renal parenchymal area as a predictor of early end-stage renal disease in children with vesicoamniotic shunting for lower urinary tract obstruction. ( 30093259 )
2018
37
ARFI shear-wave elastography with simulation of acute urinary tract obstruction in an ex vivo porcine kidney model. ( 30211684 )
2018
38
Antenatal intervention for congenital fetal lower urinary tract obstruction (LUTO): a systematic review and meta-analysis. ( 30501534 )
2018
39
Cloacal Anomalies in Monoamniotic, Monochorionic Twins with Complete Urinary Tract Obstruction. ( 30540986 )
2018
40
Response to commentary to 'The search for the definition and effective diagnosis of upper urinary tract obstruction: the Whitaker test then and now'. ( 30579609 )
2018
41
The search for the definition, etiology, and effective diagnosis of upper urinary tract obstruction: the Whitaker test then and now. ( 30602417 )
2018
42
Laparoscopic resection of large pelvic lipoma causing obstructive uropathy in a 66 year old female - A case report from Greece. ( 30317275 )
2018
43
An Unusual Presentation of Metastatic Urothelial Bladder Carcinoma With Rhabdoid Features Presenting as Obstructive Uropathy. ( 29288786 )
2018
44
Obstructive uropathy in a patient with double district ureter. ( 29229357 )
2018
45
Value of Magnetic Resonance Urography Versus Computerized Tomography Urography (CTU) in Evaluation of Obstructive Uropathy: An Observational Study. ( 29399012 )
2018
46
Urinary antimicrobial peptides: Potential novel biomarkers of obstructive uropathy. ( 29706289 )
2018
47
The results of ultrasound-guided percutaneous nephrostomy tube placement for obstructive uropathy: A single-centre 10-year experience. ( 29799408 )
2018
48
Unusual cause of obstructive uropathy: bilateral steinstrasse. ( 29871965 )
2018
49
From a stone to rupture: calyceal rupture secondary to obstructive uropathy. ( 29881597 )
2018
50
Obstructive Uropathy and Sepsis Caused by an Inguinoscrotal Bladder Hernia: A Case Report. ( 30005731 )
2018
Sources

Variations for Urinary Tract Obstruction

About this section
Sources

Expression for Urinary Tract Obstruction

About this section
Search GEO for disease gene expression data for Urinary Tract Obstruction.
Sources

Pathways for Urinary Tract Obstruction

About this section

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
HIV Life Cycle 67
Show member pathways
 13.69 ALB B2M EGF FN1 HBEGF PIK3CA
2
Cytokine Signaling in Immune system 67
Show member pathways
 13.3 B2M CCL2 EGF FN1 HBEGF PIK3CA
3
p70S6K Signaling 65
Show member pathways
 12.99 CCL2 CCN2 EGF HBEGF PTGS2 REN
4
Human cytomegalovirus infection 38
Show member pathways
 12.92 B2M CCL2 PIK3CA PTGS2 SMAD3 TGFB1
5
Endometrial cancer 38
Show member pathways
 12.82 EGF KLK3 PIK3CA SMAD2 SMAD3 TGFB1
6
Gastric cancer 38
Show member pathways
 12.73 EGF PIK3CA SMAD2 SMAD3 TGFB1
7
Pathways in cancer 38
12.65 EGF FN1 KLK3 PIK3CA PTGS2 SMAD2
8
ErbB signaling pathway 1 38
Show member pathways
 12.55 EGF HBEGF PIK3CA TGFB1
9
Development EGFR signaling pathway 23
Show member pathways
 12.44 EGF HBEGF PIK3CA SMAD2 SMAD3 TGFB1
10
Human T-cell leukemia virus 1 infection 38
12.32 PIK3CA SMAD2 SMAD3 TGFB1
11
Selenium Micronutrient Network 1
Show member pathways
 12.29 ALB CCL2 GGT1 PTGS2
12
Proteoglycans in cancer 38
12.23 FN1 HBEGF PIK3CA SMAD2 TGFB1
13
Wnt / Hedgehog / Notch 4
12.2 CCN2 SMAD2 SMAD3 TGFB1
14
Cellular senescence (KEGG) 38
12.13 PIK3CA SMAD2 SMAD3 TGFB1
15
Hippo signaling pathway 38
12.11 CCN2 SMAD2 SMAD3 TGFB1
16
Colorectal Cancer Metastasis 65
12.11 EGF PTGS2 SMAD2 SMAD3 TGFB1
17
NRF2 pathway 1
12.07 GGT1 HBEGF SLC5A6 TGFB1
18
TGF-beta Signaling Pathway (WikiPathways) 1
12.03 FN1 SMAD2 SMAD3 TGFB1
19
FoxO signaling pathway 38
Show member pathways
 11.94 EGF PIK3CA SMAD2 SMAD3 TGFB1
20
Interleukin-4 and 13 signaling 67
11.93 CCL2 FN1 PTGS2 TGFB1
21
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.93 CCL2 CCN2 EGF PIK3CA SMAD2 SMAD3
22
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 11.9 EGF HBEGF KLK3 PIK3CA SMAD3 TGFB1
23
Amoebiasis 38
11.85 FN1 PIK3CA TGFB1
24
TGF-beta Signaling Pathways 66
11.85 SMAD2 SMAD3 TGFB1
25
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.83 SMAD2 SMAD3 TGFB1
26
Small cell lung cancer 38
11.83 FN1 PIK3CA PTGS2
27
TGF-beta signaling pathway (KEGG) 38
11.82 SMAD2 SMAD3 TGFB1
28
Angiogenesis (CST) 4
11.79 CCL2 PTGS2 REN TGFB1
29
Development_TGF-beta receptor signaling 23
11.7 SMAD2 SMAD3 TGFB1
30
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.69 CCL2 PTGS2 TGFB1
31
TGF-beta receptor signaling activates SMADs 67
Show member pathways
 11.68 SMAD2 SMAD3 TGFB1
32
Regulation of Telomerase 1
11.65 EGF SMAD3 TGFB1
33
Lung fibrosis 1
11.61 CCL2 CCN2 EGF TGFB1
34
Cell adhesion_ECM remodeling 23
11.6 FN1 HBEGF KLK3
35
Hepatitis C and Hepatocellular Carcinoma 1
11.52 PTGS2 SMAD3 TGFB1
36
TGF-beta Receptor Signaling (WikiPathways) 1
11.52 EGF SMAD2 SMAD3 TGFB1
37
Cell adhesion_Plasmin signaling 23
11.49 FN1 PIK3CA TGFB1
38
TGF-beta receptor signaling (Pathway Interaction Database) 1
11.44 CCN2 SMAD2 SMAD3 TGFB1
39
Extracellular vesicle-mediated signaling in recipient cells 1
11.24 SMAD2 SMAD3 TGFB1
40
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
11.13 CCN2 SMAD2 SMAD3
41
IL1 and megakaryocytes in obesity 1
11.12 CCL2 HBEGF PIK3CA
42
IL-2 Gene Expression in Activated and Quiescent T-Cells 65
Show member pathways
 11.12 EGF HBEGF PIK3CA SMAD2 SMAD3 TGFB1
43
AGE-RAGE signaling pathway in diabetic complications 38
11.1 CCL2 FN1 PIK3CA SMAD2 SMAD3 TGFB1
44
G-protein signaling_Rap2B regulation pathway 23
10.99 CCL2 CCN2 EGF FN1 TGFB1
45
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.71 FN1 SMAD2 SMAD3 TGFB1
Sources

GO Terms for Urinary Tract Obstruction

About this section

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ALB B2M CCL2 CCN2 EGF FN1
2 endoplasmic reticulum lumen GO:0005788 9.71 ALB B2M FN1 PTGS2
3 platelet alpha granule lumen GO:0031093 9.46 ALB EGF FN1 TGFB1
4 extracellular space GO:0005615 9.4 ALB B2M CCL2 CCN2 EGF FN1
5 SMAD protein complex GO:0071141 9.37 SMAD2 SMAD3
6 heteromeric SMAD protein complex GO:0071144 9.26 SMAD2 SMAD3
7 extracellular exosome GO:0070062 10.02 ALB AQP2 B2M EGF FN1 GGT1

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.98 EGF HBEGF SMAD3 TGFB1
2 MAPK cascade GO:0000165 9.95 CCL2 EGF HBEGF TGFB1
3 cytokine-mediated signaling pathway GO:0019221 9.95 CCL2 FN1 PIK3CA PTGS2 TGFB1
4 cellular protein metabolic process GO:0044267 9.94 ALB B2M FN1 KLK3
5 cell migration GO:0016477 9.93 CCN2 HBEGF PIK3CA TGFB1
6 positive regulation of protein kinase B signaling GO:0051897 9.91 EGF HBEGF PIK3CA TGFB1
7 response to lipopolysaccharide GO:0032496 9.91 GGT1 PTGS2 REN SLPI
8 transforming growth factor beta receptor signaling pathway GO:0007179 9.87 SMAD2 SMAD3 TGFB1
9 response to organic substance GO:0010033 9.86 PTGS2 REN TGFB1
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 EGF HBEGF TGFB1
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 PIK3CA PTGS2 TGFB1
12 positive regulation of gene expression GO:0010628 9.85 CCN2 EGF FN1 SMAD2 SMAD3 TGFB1
13 response to glucose GO:0009749 9.84 CCN2 SMAD2 TGFB1
14 platelet degranulation GO:0002576 9.84 ALB EGF FN1 TGFB1
15 response to wounding GO:0009611 9.83 CCN2 FN1 TGFB1
16 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.83 SMAD2 SMAD3 TGFB1
17 SMAD protein signal transduction GO:0060395 9.8 SMAD2 SMAD3 TGFB1
18 response to estradiol GO:0032355 9.78 CCN2 GGT1 PTGS2 TGFB1
19 positive regulation of epithelial to mesenchymal transition GO:0010718 9.77 SMAD2 SMAD3 TGFB1
20 ureteric bud development GO:0001657 9.76 SMAD2 SMAD3 TGFB1
21 protein kinase B signaling GO:0043491 9.74 CCL2 PIK3CA TGFB1
22 wound healing GO:0042060 9.71 FN1 SMAD2 SMAD3 TGFB1
23 positive regulation of protein import into nucleus GO:0042307 9.7 PTGS2 SMAD3 TGFB1
24 endoderm development GO:0007492 9.69 SMAD2 SMAD3 TGFB1
25 lens fiber cell differentiation GO:0070306 9.68 SMAD3 TGFB1
26 nodal signaling pathway GO:0038092 9.67 SMAD2 SMAD3
27 primary miRNA processing GO:0031053 9.67 SMAD2 SMAD3
28 response to cholesterol GO:0070723 9.67 SMAD2 TGFB1
29 ERBB2 signaling pathway GO:0038128 9.67 EGF HBEGF PIK3CA
30 embryonic foregut morphogenesis GO:0048617 9.65 SMAD2 SMAD3
31 pericardium development GO:0060039 9.64 SMAD2 SMAD3
32 angiogenesis GO:0001525 9.63 CCL2 CCN2 EGF FN1 PIK3CA PTGS2
33 common-partner SMAD protein phosphorylation GO:0007182 9.62 SMAD2 TGFB1
34 positive regulation of extracellular matrix assembly GO:1901203 9.6 SMAD3 TGFB1
35 regulation of striated muscle tissue development GO:0016202 9.58 SMAD3 TGFB1
36 epidermal growth factor receptor signaling pathway GO:0007173 9.56 EGF HBEGF PIK3CA TGFB1
37 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.5 SMAD2 SMAD3 TGFB1
38 evasion or tolerance of host defenses by virus GO:0019049 9.46 SMAD3 TGFB1
39 paraxial mesoderm morphogenesis GO:0048340 9.43 SMAD2 SMAD3
40 SMAD protein complex assembly GO:0007183 9.13 SMAD2 SMAD3 TGFB1
41 regulation of binding GO:0051098 8.8 SMAD2 SMAD3 TGFB1
42 negative regulation of cell proliferation GO:0008285 10.03 PTGS2 SMAD2 SMAD3 TGFB1 UMOD
43 positive regulation of cell proliferation GO:0008284 10.03 CCN2 EGF FN1 HBEGF PTGS2 TGFB1

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.65 FN1 PTGS2 SLPI SMAD3 TGFB1
2 enhancer binding GO:0035326 9.46 SMAD2 SMAD3
3 growth factor activity GO:0008083 9.46 CCN2 EGF HBEGF TGFB1
4 co-SMAD binding GO:0070410 9.43 SMAD2 SMAD3
5 type I transforming growth factor beta receptor binding GO:0034713 9.4 SMAD2 TGFB1
6 primary miRNA binding GO:0070878 9.32 SMAD2 SMAD3
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.07 PIK3CA
8 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 8.96 SMAD2 SMAD3
9 transforming growth factor beta receptor binding GO:0005160 8.8 SMAD2 SMAD3 TGFB1
Sources

Sources for Urinary Tract Obstruction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....